AI company Azra AI, has launched the newest release of its end-to-end oncology platform which enables personalised cancer treatment plans.
Azra AI’s platform provides support for the full continuum of care using advanced AI models trained on over 100 million pathology and radiology reports.
According to the company, the Pathology AI models identify newly diagnosed cancer patients, surfacing cases by primary site, stage, tumour markers, and other clinical characteristics.
The Radiology AI models detect suspicious incidental findings across lung, pancreas, liver, ovarian and endometrial, colon, neuro, and more – prioritising high-risk findings that might otherwise go unnoticed.
Azra also structures unstructured data from cancer screens to ensure patients receive necessary follow-up.
“With cancer rates on the rise, health systems face mounting pressure to move beyond inefficient, manual processes,” said John Marshall, CEO of Azra AI.
“Our platform addresses these challenges by equipping oncology teams with advanced technology that automates critical oncology workflows throughout the entire oncology service line – all while eliminating the complexity and inefficiencies of fragmented point solutions.
“Ultimately, we empower care teams to focus on what matters most: delivering exceptional, patient-cantered care.
“Oncology service lines need proven technology to run smoothly. Dealing with multiple vendors to piece together that technology is a headache for IT and a pain for users—it just doesn’t work long-term.
“That kind of patchwork approach is messy, expensive, and risky. At Azra, we built a single platform that takes care of it all, and that’s a big reason why we’re seeing so much success and healthcare organisations are seeing greater positive impact.”
